Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
1. Detection of unexpected Adverse Drug Reactions
2. To grasp development of Adverse Drug Reactions
3. To grasp contributing factors possibly having an impact on the safety and efficacy
4. Development of key investigational safety specification (serious infection).
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The evaluable patients treated with Fasenra for the first time due to "Bronchial asthma (only the patients with intractable bronchial asthma which could not be controlled with the existing therapy).
You may not be if
No past history of hypersensitivity to the components of Fasenra.
